💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Obecabtagene Autoleucel

CHEMBL5095440 Phase 4 Aprobado Gene
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A CAR-T cell therapy in which a patient's own T cells are engineered to express a chimeric antigen receptor targeting CD19, used to treat relapsed or refractory B-cell acute lymphoblastic leukemia and other B-cell malignancies. The modified cells are infused back into the patient, where they recognize and destroy CD19-positive cancer cells.

Áreas terapéuticas

Esclerosis múltiple Leucemia Linfoma Lupus eritematoso sistémico

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A CAR-T cell therapy in which a patient's own T cells are engineered to express a chimeric antigen receptor targeting CD19, used to treat relapsed or refractory B-cell acute lymphoblastic leukemia and other B-cell malignancies. The modified cells are infused back into the patient, where they recognize and destroy CD19-positive cancer cells.

Yes, Obecabtagene Autoleucel is an approved drug. It has reached clinical phase 4. It is classified as a Gene.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5095440. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.